Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This research study tests whether GLYX-13 - an experimental drug that acts on a brain
receptor called NMDA - can decrease symptoms of OCD within hours. This is not a treatment
study. Results from this study will allow doctors and researchers to better understand if you
and others with OCD may respond to a class of medications that target the NMDA brain
receptor.